DiamiR, a developer of innovative blood-based diagnostic tests for brain health and other diseases, today announced that it has entered into a definitive agreement to acquire a CLIA (Clinical Laboratory Improvement Amendments) certified laboratory in New Haven, CT from Interpace Biosciences, Inc. Subject to specific terms and conditions of the agreement being met, it is anticipated that the transaction will close by the end of April 2021. The financial terms of this transaction have not been disclosed.
“Acquisition of this CLIA-certified lab facility significantly expands DiamiR’s capabilities to develop and commercialize our microRNA-based tests for early detection, differential diagnosis, prediction of progression and monitoring of brain health and other conditions,” commented Dr. Samuil Umansky, President and Chief Scientific Officer of DiamiR. “It is especially timely as our lead pipeline product, CogniMIR™, for mild cognitive impairment and Alzheimer’s disease enters late stages of development and validation. CogniMIR™ combines brain-enriched and inflammation-associated microRNA biomarkers detectable in blood plasma and algorithm classifier. DiamiR’s other programs focus on the analysis of circulating organ-enriched microRNAs as peripheral epigenetic biomarkers of disease severity and progression as well as response to treatment during drug development.”
Source: Biospace
